Why is Twist Bioscience stock plunging today?
Twist Bioscience (TWST) shares fell 16.1% to $171.96 after ARK Invest sold $18M worth of shares, marking 21 straight sessions of selling. Insiders also sold shares, and the stock is 42.9% above its fair value estimate. Analysts' average price target is $115.27, suggesting significant downside from the prior close of $205.
How this was made
The 30-second read
Why it matters
The combined ARK and insider sell‑offs triggered a 16% intraday plunge, indicating strong short‑term bearish pressure.
Market read
The article documents a material price move driven by new institutional and insider selling, relevant for short‑term traders.
What to watch
Potential upcoming product milestones or partnership announcements could offset the selling pressure.
Background
Twist Bioscience is a high‑growth synthetic‑biology firm that has attracted activist interest from ARK Invest. Recent insider sales add to the negative sentiment.
Ticker impact
Twist Bioscience shares fell 16.1% after ARK Invest disclosed its 21st consecutive day of selling and multiple insiders sold shares.
likely further downside as the market prices in continued selling pressure
Large, repeated ARK sales and insider disposals signal weak sentiment and overvaluation, prompting mean‑reversion trades.
Market effects
Highlights volatility risk in synthetic biology and biotech stocks when large activist funds divest.
Limited to U.S. biotech equities; broader indices rose despite the drop.
Minimal; the move is company‑specific.
Counterpoint
If the sell‑off is over‑reacted, the stock may be oversold and present a short‑term buying opportunity.
Key entities
- institutional investorARK Invest
Active shareholder reducing its position in Twist Bioscience for the 21st day.
- executiveEmily M. Leproust
CEO and director filing a proposed sale of 4,548 shares.
